From the early days of MS discovery, infections have been proposed as a possible cause of the disease. In the last three decades, an association between human endogenous retrovirus expression and MS has been further investigated and confirmed. Nevertheless, the role of such retroviruses in the disease needs clarification. In this review, we introduce MSRV/HERV-W and describe its association with MS. We then summarize the evidence for the involvement of MSRV/HERV-W in the aetiology and progression of MS and its possible role as biomarker and drug target. Biological mechanisms for HERV effects in MS may involve the activation of innate immune pathways by the envelope protein of MSRV (MSRVEnv). In addition to in vitro and experimental studies, further insight on how HERVs may influence immune-mediated pathology in MS may also come from the use of antiretroviral treatments in patients.
Introduction
From the early discovery and description of multiple sclerosis (MS), and particularly since John Kurtzke's seminal epidemiological observations, 1 infections have been proposed to be involved in MS pathogenesis. Indeed, although familial aggregation of MS cases and high MS prevalence in some ethnic populations demonstrate a genetic predisposition, latitudedependent north-to-south gradient of disease incidence and migration studies point to an environmental component. Historically, the epidemiology of infectious triggers for MS has been described by two main hypotheses: 2 the 'Prevalence hypothesis' 1 and the 'Hygiene hypothesis'. 3 The first suggests that MS is caused by a pathogen that is more prevalent in areas with high incidence of MS. This agent causes an asymptomatic persistent infection in most individuals, and only rarely causes neurological symptoms, several years after the primary infection. The second theory postulates that early exposure to certain pathogens is protective against immune-mediated diseases, whereas their late acquisition confers a higher risk of developing autoimmunity and allergy. 1, 3 In this review, we will consider a third theory, in which an exogenous factor can induce the expression of genetically transmitted endogenous retroviruses.
Human endogenous retroviruses
Human endogenous retroviruses (HERVs) integrated into human germ line cells 70-30 million years ago, becoming part of the human DNA and being transmitted through the generations. They represent up to 8% of the human genome. HERVs are classified into three classes based on their sequence identity with known exogenous retroviruses: class I, II and III, similar to gammaretroviruses, betaretroviruses, or spumaviruses, respectively. These classes are further divided into at least 31 families in which the letter added to HERV (HERV-W, HERV-K, HERV-H, etc.) corresponds to the transfer RNA (tRNA) specificity of the primer binding site.
HERVs have the same genetic structure as exogenous retroviruses. Two LTR (long terminal repeat) regions delimit the genome that encodes four major viral proteins: Gag, the matrix and retroviral core; Pol, the reverse transcriptase; Pro, the integrase; and Env, the envelope ( Figure 1 ). HERV expression is regulated by the promoter and enhancer regions in the LTR. In transmission over generations, endogenous retroviruses generally accumulate a series of mutations and recombination events that only permit their RNA and protein expression. Accordingly, to date no human ERVs has been shown to be fully able to replicate and produce infectious virions.
Even though mutations and cellular control mechanisms can prevent their expression, probably between 7% and 30% of all HERV sequences in the genome are transcriptionally active, the extent of expression varying from tissue to tissue and between individuals. Their activity is increased in pathological conditions, such as cancer, neurological and autoimmune diseases. 4
Association between HERVs and MS
A report published in 1989 by Perron et al. 5 showed for the first time the presence of retroviral transcriptional activity in leptomeningeal cells from MS patients. The newly discovered retrovirus was named multiple sclerosis-related retrovirus (MSRV). Different groups have subsequently studied possible correlations between the expression of endogenous retroviruses and MS, but the literature on this topic has been confused due to the different methods used, different patient cohorts and sample types and the variety of names given to the sequences detected. Indeed, initial studies on MSRV/HERV-W 5 focussed on detection of cell-free MSRV virions assuming that functional viral particles were involved, but it has been since discovered that MSRV/HERV-W sequences are replication incompetent and that they originate from a mosaic of loci. 6 In a systematic review, we summarized the evidence for an association between HERVs and MS. 7 We found that in the currently available literature, MSRV/HERV-Wenv and pol DNA copy number, RNA and protein expression were increased in serum/plasma, cerebrospinal fluid (CSF) and peripheral blood mononuclear cells (PBMC) of MS patients compared to control groups (including healthy subjects or those with other neurological diseases). The studies we analysed used different techniques: reverse transcription polymerase chain reaction (RT-PCR), flow cytometry and enzymelinked immunosorbent assay (ELISA). In a meta-analysis, we also quantified the association between the MSRV/HERV-W with MS finding an odds ratio (OR) = 22.66 (95% confidence interval (CI): 6.32-81.20) for MSRV/HERV-Wenv in PBMC, OR = 44.11 (95% CI: 12.95-150.30) for MSRV/HERV-Wpol in serum/plasma and OR = 6.00 (95% CI: 3.35-10.74) for MSRV/HERV-Wpol in CSF. 7 Although this meta-analysis presents some limitations, such as the low number of studies that met the inclusion criteria and the small size of the populations taken into account, this is a strong indicator of the high expression of MSRV/ HERV-W in MS. Basal expression of MSRV/HERV-W was present in astrocytes, monocytes, natural killer (NK) and B cells and it was higher in MS patients. By contrast, the endogenous retrovirus was not expressed in T cells. 8, 9 Some studies 10, 11 have also reported the presence of this retrovirus in the brain of MS patients, but two research groups 12,13 did not confirm this association, possibly due to differences in the techniques used or in the genetics of the populations studied.
Other HERV families including: HERV-H (in particular, the single-nucleotide polymorphism (SNP) rs391745 on HERV-Fc1), HERV-K (in particular, the polymorphism HERV-K18) and HRES (human T-cell leukaemia virus-related endogenous sequence) have also been associated with MS, although fewer studies are available. 7
Repression and activation of HERVs in MS
It is still not completely established why some of these endogenous retroviruses are expressed in particular pathological conditions. In addition to the inactivation of the retrovirus due to mutations, there are different intracellular factors that can influence and restrict HERV replication. Epigenetic mechanisms are involved, through which cellular proteins can methylate DNA and bring histone modification to silence or repress viral RNA transcription. 14 A direct link between MS and altered epigenetic regulation has already been reported in studies on the immunopathology of MS, in particular, on the differentiation of Th1, Th2 and Th17 cells and on cytokine production. 15 Similar epigenetic alterations could influence the expression of HERVs.
Other mechanisms include retroviral restriction factors, which are a set of cellular proteins that play an integral role in suppression of exogenous and endogenous retroviruses in normal tissues. They have also been shown to inhibit replication of several other classes of viruses, including herpesviruses and influenza viruses. At least five groups of retroviral restriction factors have been robustly identified so far. They target viral uncoating and reverse transcription (the APOBEC family of genes, type 1 interferon-inducible tripartite motif (TRIM) E3 ligases and SAMHD1), translation (Schlafen11) and release (Tetherin). Interestingly, SNPs in two restriction factors of the TRIM family (TRIM5α and TRIM22) have been associated with MS, supporting the hypothesis of their role in disease pathogenesis. 16 These proteins interfere with retroviral replication by interacting with the viral capsid and targeting its core to the ubiquitin-proteasome pathway for degradation (TRIM5α) or interfering with viral gene transcription (TRIM22).
In addition to intrinsic factors, external events, and in particular viral infections, can act as activators of HERV expression, or de-regulators of the mechanisms that normally prevent HERV expression, either at the time of infection or via longer term epigenetic modification. In culture, the expression of MSRV/HERV-W genes/ proteins is activated by Epstein Barr virus (EBV), herpes simplex virus type 1 and by influenza virus, but not by rabies virus. 17 Interestingly the Herpesviridae, a virus family that can activate HERV-W, are also strongly associated with MS in epidemiological studies. For instance, the risk of developing MS for EBVseronegative individuals is at least 15 times lower than in those with prior infection with EBV. 2 The binding of the EBV gp350 protein can activate the expression of MSRV/HERV-W in peripheral blood cells and in astrocytes. 9 Moreover, in infectious mononucleosis (IM), a clinical manifestation of EBV that often occurs after infection post-childhood, the expression of MSRV/ HERV-W in blood mononuclear cells of patients is increased. 18 The expression of MSRV/HERV-W also increases in patients with high levels of anti-EBNA IgG, a marker of past EBV infection.
HERVs in MS aetiology
Little is known about the effect of HERVs on the immune system, but some groups have shown that HERV-W/MSRV can activate innate immunity by pattern recognition receptors (PRR) expressed on antigen presenting cells (APC). In the circulation, MSRVEnv can specifically activate monocytes and endothelial cells through CD14/TLR4 and activate the production of proinflammatory cytokines such as interleukin (IL)-1β, IL-6 and tumour necrosis factor (TNF)-α. [19] [20] [21] The same protein can induce phenotypic and functional maturation of dendritic cells and confers them the ability to support the development of Th1-like effector T-lymphocytes. 20 At the brain level, the activation of TLR4 by HERV-WEnv in oligodendroglial precursor cells leads to the production of proinflammatory cytokines as well as inducible nitric oxide synthase (iNOS), the formation of nitro-tyrosine groups and a reduction in myelin protein expression. 22 In addition, in chronic active MS brain lesions, HERV-WEnv has been detected in microglia/macrophages in proximity to TLR4-positive oligodendroglial precursor cells. 22 In addition, MSRV/HERV-WEnv has been shown to have properties similar to a superantigen (a protein that can elicit an antigen-independent polyclonal activation of T lymphocytes) activating polyclonal V16 T-lymphocytes in vitro 23 and causing significant neuropathology in a human T-cell-grafted severe combined immunodeficiency (SCID) mouse model. 24 A further mechanism of action is suggested by the MSRV receptor. As with all exogenous retroviruses, HERV-W proteins have a cellular receptor: the sodium-dependent neutral amino acid transporter type 1 and type 2 (ASCT-1 and ASCT-2). ASCT-1 is predominantly expressed on brain astrocytes and is the main transporter of l-serine, an astrocyte-derived neurotrophic factor that is essential for myelination and neuronal survival. This receptor is suppressed in the white matter of MS patients and the binding of HERV-W results in a downregulation of the ASCT-1. This interaction, in turn, induces the expression of an endoplasmic reticulum stress sensor and of iNOS, causing oxidative stress. 25 This evidence suggests that there are a number of plausible mechanisms for the involvement of MSRV/ HERV-W in the immunopathological cascades associated with MS. This pathogenic role has been demonstrated in C57BL/6 mice, where the administration of the MSRVEnv emulsified with MOG can induce experimental autoimmune encephalomyelitis (EAE) with clinical and histopathological features indistinguishable from those of standard EAE, thus substituting for adjuvant. 26 In addition to the HERV-W family, HERV-K has also been shown to have pathogenic potential. HERV-K18env encodes a superantigen that can be transactivated by EBV proteins LMP-2A and CD21 through its ITAM (immunoreceptor tyrosine-based activation motif) in infected B lymphocytes. 27 
HERVs in MS progression
Several studies in MS patients show MSRV/HERV-W correlation with MS disease and prognosis. A higher expression of MSRV/HERV-Wenv RNA has been found in secondary progressive multiple sclerosis (SPMS) compared to relapse-remitting multiple sclerosis (RRMS) and patients with an elevated MSRV/ HERV-Wenv DNA copy number had a higher Expanded Disability Status Scale (EDSS) score. A 10-year blind observational study showed evidence that the presence of MSRV/HERV-W in the cerebrospinal fluid of early MS patients is associated with a significantly higher relapse rate, EDSS score and probability to reach secondary progression. 28 This endogenous retrovirus could also be involved in disease progression by facilitating maintenance of chronic inflammatory state. Studies on the disease-modifying immunotherapies Natalizumab 29 and interferon (IFN)-β 30 indicate that these drugs can inhibit the expression of HERV-W/MSRV in MS patients after 3 and 6 months of therapy, suggesting that decreased inflammation reduces the expression of MSRV/HERV.
HERVs as MS biomarkers and drug targets
The association between MSRV/HERV-W expression and MS disease and progression makes MSRV/ HERV-W a good biomarker candidate as a diagnostic and prognostic factor. The virus can be easily detected in serum of patients, but for now the lack of a standard and optimized technique is the major issue for the use of this biomarker in clinics. 31 Moreover, the potential different levels of expression of MSRV/HERV-W in different genetic populations 7 could create a strong bias.
A humanized antibody called GNbAC1 has been developed to specifically target MSRV/HERV-W. In a phase I clinical study, the antibody safety was tested in 33 healthy male subjects 32 with no adverse events reported. Subsequently, a phase IIa, single-blind, placebo-controlled, dose-escalation randomized study with an open-label extension up to 12 months of treatment was performed. 33 The goal of the study was to assess the safety, immunogenicity, pharmacodynamics and pharmacokinetics of repeated administrations of GNbAC1 in people with MS. A total of 10 patients were enrolled (3 women and 7 men; 1 RRMS, 3 primary progressive multiple sclerosis (PPMS) and 6 SPMS) and divided into two dose cohorts of five patients each. Four patients were blindly randomized to receive GNbAC1 and one patient to receive placebo for the first administration, then all patients of the two dose cohorts received 11 open-label infusions of GNbAC1 (either at 2 or at 6 mg/kg) at 4-week intervals. 33 A decrease in MSRV/HERV-Wenv and MSRV/ HERV-Wpol transcripts levels was observed at 3 and 6 months of treatment. After 12 months of follow-up, the pharmacodynamics and pharmacokinetics were assessed, with no evidence of significant toxicity or immunogenicity. Magnetic resonance imaging (MRI) appearances were stable at 6 months in 9 of the 10 MS patients; the 10th patient had a new T2 lesion and dropped out after 6 months. 33, 34 A longer observation will be required to assess the real efficacy of the drug.
Association between HIV and MS
A further connection between HERVs and MS is supported by an observation that people infected by HIV may have a lower risk of developing MS than the noninfected healthy population. A recent comparative cohort study 35 examined the association between HIV and MS using an English medical database with a cohort of 21,207 HIV-positive patients and 5,298,496 controls stratified by age, sex, year of first hospital admission, region of residence and socioeconomic status. They calculated that the incidence rate ratio of developing MS was statistically significantly lower in people with HIV compared to those without (0.38 (95% CI: 0.15-0.79)). The authors discussed two different hypotheses that could explain this correlation. The first is related to the HIV viral infection itself. Because HIV targets CD4+ lymphocytes, the reduction of CD4+ T cells in infected people could decrease the possibility of autoimmunity and therefore reduce the risk of developing MS. But this is not the case for other autoimmune diseases: the list of reported autoimmune diseases in HIV/AIDS patients includes rheumatological syndromes, systemic lupus erythematosus, anti-phospholipid syndrome, vasculitis, primary biliary cirrhosis, polymyositis, Graves' disease and idiopathic thrombocytopenic purpura. 36 There are isolated case reports of HIV-positive patients developing MS or central nervous system (CNS) demyelinating disorders after HIV infection, [37] [38] [39] arguing that HIV itself probably cannot protect from MS. However, there are also reports of HIV-infected MS patients experiencing improvement or sustained remission of neurological deficits after starting active antiretroviral therapy (ART). 37, 40, 41 Unfortunately, in the comparative cohort study published by Gold et al., 35 the authors did not have data available on retroviral drug therapy, but we can assume that the majority of the patients were treated as is the norm in high-income countries. ART acts not only against HIV but may also inhibit endogenous retroviruses, thus potentially preventing the development of MS. A phase II clinical trial (INSPIRE) studying the effect of the antiretroviral drug raltegravir, an integrase inhibitor, on RRMS patients has recently been completed. 42 There were no significant effects on inflammatory activity assessed by MRI. However, it is possible that classes of antiretroviral drugs that target other stages of the retroviral lifecycle, or their combinations, could still be effective.
Conclusion
In conclusion, the association between HERVs and MS is quite strong. MSRV/HERV-W has the pathogenic potential to activate inflammatory immunity, which could be relevant to both disease susceptibility and progression. There remains a possibility that the increased retroviral expression in MS patients is a consequence of inflammation, although the balance of evidence clearly favours a pathogenic role. Taking in consideration the multifactorial aetiology of MS, it is likely that increased expression of MSRV/HERV-W is a significant contributing factor in genetically predisposed individuals. If these observations are further substantiated, future personalised treatments of MS may well include antiretroviral drugs.
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